InCl₃-Catalyzed stereoselective synthesis of 1,5-benzodiazepines

J.S. Yadav,* B.V.S. Reddy, G. Satheesh G. Srinivasulu, and A. C. Kunwar

Organic Chemistry Division I, Indian Institute of Chemical Technology, Hyderabad 500 007, India E-mail: <u>yadav@iict.res.in</u>

Dedicated to Dr. A. V. Rama Rao on his 70th birthday (received 10 Dec 04; accepted 16 Feb 05; published on the web 17 Feb 05)

Abstract

o-Phenylenediamines (OPDA) undergo smooth condensation with 4,6-di-*O*-benzyl- or 4,6-di-*O*-acetyl- or 4,6-di-*O*-ethyl-2,3-dideoxy-*aldehydo*-D-*erythro-trans*-hex-2-enose derived from D-glucal in the presence of 2 mol% of $InCl_3$ under mild conditions to afford a new class of 1,5-benzodiazepines in good yields.


Keywords: *vic*-Diamines, α , β -unsaturated- δ -hydroxyaldehyde, diazepines

Introduction

Benzodiazepines have recently received great importance because of their wide range of therapeutic and pharmacological properties. Many members of diazepine family are nowadays widely used as anticonvulsant, antianxiety, analgesic, sedative, antidepressive, and hypnotic agents.^{1.2} Benzodiazepine derivatives also find commercial use as dyes for acrylic fibers³ and as anti-inflammatory agents.⁴ In addition, 1,5-benzodiazepines are key intermediates for the synthesis of various fused ring compounds such as triazolo-, oxadiazolo-, oxazino-, or furano-benzodiazepines.⁵ As a result, various methods have been developed for the synthesis of 1,5-benzodiazepines.^{6,7} Due to their wide range of biological, industrial and synthetic applications, the development of mild and efficient protocols continues to be a challenging endeavor in synthetic organic chemistry. In recent years, indium chloride has evolved as mild and water-tolerant Lewis acid imparting high regio-, stereo- and chemoselectivity in various organic transformations.⁸ Compared to conventional Lewis acids, indium trichloride in particular has advantages of low catalyst loading, moisture stability and catalyst recycling. However, there have been no reports on the synthesis of diazepines from α,β -unsaturated sugar aldehyde and *o*-phenylenediamines.

Results and Discussion

In this article, we describe a novel and rapid approach for the synthesis of 1,5-benzodiazepines from *o*-phenylenediamines and 4,6-di-*O*-substituted-2,3-dideoxy-*aldehydo*-D-*erythro-trans*-hex-2-enose⁹ using indium(III)chloride as a catalyst. Accordingly, treatment of *o*-phenylenediamine **1** with 4,6-di-*O*-benzyl-2,3-dideoxy-*aldehydo*-D-*erythro-trans*-hex-2-enose **2** in the presence of 2 mol% of InCl₃ in ethanol at room temperature afforded 1,5-benzodiazepine **3a** in 85% yield (Scheme 1).



Scheme 1

The structure of the product 3a was established by using various solution NMR experiments like DQFCOSY, NOESY and HSQC. The HSQC spectrum showed that the presence of four CH₂ and eight CH's in the product 3a.





Figure 1. Schematic diagram with long range nOes of 3a.

In a similar manner, various substituted *o*-phenylenediamines such as 4-methyl-, 4,5dimethyl-, reacted rapidly with 4,6-di-*O*-benzyl-2,3-dideoxy-*aldehydo*-D-*erythro-trans*-hex-2enose to give the corresponding benzodiazepine derivatives (entries **1a-c** Table 1). Other substrates such as 4,6-di-*O*-ethyl- and 4,6-di-*O*-acetyl-2,3-dideoxy-*aldehydo*-D-*erythro-trans*hex-2-enose gave the respective substituted 1,5-benzodiazepines in good yields under similar conditions (entries **d-g**, Table 1). All the products were characterized by ¹H, ¹³C NMR, IR, and mass spectral analysis. The probable mechanism seems to be addition of amine to the unsaturated position of conjugated aldehyde, which is activated by indium trichloride. Thus the initially formed Michael adduct may undergo cyclization with another amino group leading to the formation of diazepine (Scheme 2).



Scheme 2

Among various acid catalysts such as CeCl₃.7H₂O, YbCl₃, YCl₃, and BiCl₃ tested, indium trichloride was found to give the best results in terms of reaction rates and conversion. Further, we have carried out the experiments using various solvents such as water, ethanol, ionic liquid [bmim]BF₄, acetonitrile and tetrahydrofuran. As a solvent, ethanol appeared to give the best results. The scope and generality of this process was illustrated with respect to various substituted diamines and unsaturated sugar aldehydes and the results are summarized in Table 1.

Conclusions

In summary, we have developed a mild, rapid and efficient method for the synthesis pure 1,5benzodiazepines through the condensation of sugar derived α,β -unsaturated- δ -hydroxyaldehydes with *o*-phenylenediamines using indium trichloride as the catalyst. The use of commercially available indium trichloride makes this method quite simple, more convenient and practical. It is entirely a novel protocol for the preparation of benzodiazepines in a single-step operation.

Experimental Section

General Procedures. IR spectra were recorded with a Perkin Elmer FTIR spectrophotometer. ¹H NMR spectra were carried out using a Bruker Avance 300, Varian Unity 400 and Varian Unity 500MHz spectrophotometer using TMS as an internal standard in CDCl₃. Mass spectra were recorded on Micro mass VG Autospec M for FABMS mass spectrometers. Melting points for all the compounds were recorded on Electrothermal-9100 instrument. The progress of all the reactions was monitored by thin-layer chromatography (TLC) using glass plates precoated with silica gel $60F_{254}$ to a thickness of 0.25mm (Merck). Column chromatography was conducted by elution of columns with silica gel 60-120 mesh using ethyl acetate and hexane as eluents.

General synthetic procedure

A mixture of *o*-phenylenediamine (1 mmol), α , β -unsaturated- δ -hydroxyaldehyde (1 mmol) and indium trichloride (0.02 mmol) in ethanol (10 mL) was stirred at room temperature for the appropriate time (Table 1). After completion of the reaction, as indicated by TLC, the reaction mixture was diluted with water and extracted by ethyl acetate (3x 10 mL). The combined organic extracts were dried over anhydrous Na₂SO₄, concentrated *in vacuo* and the resulting product was directly charged on small silica gel column and eluted with a mixture of ethyl acetate-hexane (1:9) to afford benzodiazepine. Spectral data for selected products.

1,3-Di(benzyloxy)-1-(2,3-dihydro-1*H***-benzo[b][1,4]diazepin-3-yl)-(1***S***,2***R***)-propan-2-ol (3a). Pale yellow crystalline solid, m.p. 95-97 °C; IR (KBr): 3354, 2921, 1507, 1304, 1101, 742 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): \delta 2.07 (dt, J_{\text{Ha-Hb}}=5.0 Hz, J_{\text{Hb-Hb}}=14.3 Hz, J_{\text{Hb'-Hc}}=9.1 Hz, 1H, Hb'), 2.33 (dd, J_{\text{Hb-Hc}}=3.6 Hz, J_{\text{Hb-Hb}}=14.3 Hz, 1H, Hb), 3.56 (dd, J_{\text{Hc-Hd}}=3.1 Hz, J_{\text{Hd-He}}=9.8 Hz, 1H, Hd), 3.67 (dd, J_{\text{He-Hf}}=2.1 Hz, J_{\text{Hf-Hf}}'=10.5 Hz, 1H, Hf), 3.78 (dd, J_{\text{He-Hf}}'=4.0 Hz, J_{\text{Hf-Hf}}'=10.5 Hz, 1H, Hf'), 3.80 (m, 1H, Hc), 4.16 (brs, 1H, NH), 4.56 (ABq, J=11.2 Hz, 2H, Hh and Hh'), 4.59 (ABq, J=11.2 Hz, 2H, Hg and Hg'), 5.03 (ddd, J_{\text{He-Hf}}=2.1 Hz, J_{\text{He-Hf}}'=4.0 Hz, J_{\text{Hd-He}}=9.8 Hz, 1H, He), 5.08 (d, J_{\text{Ha-Hb}}=5.0 Hz, 1H, Ha), 7.5-6.5 (m, 14H, Ar-H); ¹³C NMR (75 MHz, DMSO-d₆): \delta 138.8, 138.5, 137.1, 135.9, 128.2, 128.1, 127.5, 127.2, 119.5, 118.6, 118.4, 117.5, 77.2, 76.2, 72.2, 70.1, 69.4, 66.2, 47.1, 31.6; FABMS: m/z 415 (M⁺.) 367, 293, 277, 247, 173, 136, 115, 91, 81, 69, 55; HRMS calcd for C₂₆H₂₇N₂O₃: 415.2021 found: 415.2015.**

1,3-Di(benzyloxy)-1-(7-methyl-2,3-dihydro-1*H*-benzo[b][1,4]diazepin-3-yl)-(1*S*,2*R*)-

propan-2-ol (3b). Pale yellow crystalline solid, m.p. 62-64 °C; IR (KBr): 3356, 2917, 1597, 1495, 1306, 1102, 807, 745 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 2.05 (m, 1H), 2.16 (s, 3H), 2.31 (dd, J_{Hb-Hf} =3.71 Hz, J_{Hb-Hb} =14.8 Hz, 1H, Hb), 3.55 (dd, J_{He-Hf} =2.9 Hz, J_{Hf-Hf} '=9.6 Hz, 1H, Hf), 3.66 (dd, J_{He-Hf} '=2.2 Hz, J_{Hf-Hf} '=9.6 Hz, 1H, Hf), 3.75-3.80 (m, 2H, Hd and Hc), 4.1 (brs, 1H, NH), 4.56 (ABq, J=11.8 Hz, 2H, Hh and Hh'), 4.58 (ABq, J=11.8 Hz, 2H, Hg and Hg'), 5-5.05 (m, 1H, He), 5.06-5.1 (d, J_{Ha-Hb} =3.71 Hz, 1H, Ha), 6.36-6.56 (m, 3H, Ar-H), 7.24-7.38 (m, 10H, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 138.6, 138.3, 136.1, 135.5, 133.6, 133.0, 130.1, 130.7, 128.4, 128.2, 127.9, 127.6, 127.5, 121.8, 121.0, 120.1, 119.2, 118.3, 78.5, 73.4, 71.5, 69.7, 66.0, 49.4, 49.2, 30.5, 20.4; FABMS: m/z 430 (M⁺.) 201, 189, 175, 133, 109, 91, 79, 69, 55; HRMS calcd for C₂₇H₃₀N₂O₃: 430.2256 found: 430.2243.

1,3-Di(benzyloxy)-1-(7,8-dimethyl-2,3-dihydro-1*H*-benzo[b][1,4]diazepin-3-yl)-(1*S*,2*R*)-

propan-2-ol (3c). Pale yellow crystalline solid, m.p. 60-61 °C; IR (KBr): 3374, 3028, 2919, 2862, 1618, 1512, 1454, 1360, 1091, 1026, 866, 742, 697 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 2.05 (m, 1H), 2.16 (s, 6H), 2.31 (dd, J_{Hb-Hc} =3.71 Hz, $J_{Hb-Hb'}$ =14.8 Hz, 1H, Hb), 3.55 (dd, J_{He-Hf} =2.9 Hz, _{Hf-Hf}'=9.6 Hz, 1H, Hf), 3.65 (dd, J_{He-Hf} '=2.2 Hz, J_{Hf-Hf} '=9.6 Hz, 1H, Hf), 3.74-3.79 (m, 2H, Hd and Hc), 4.1 (d, *J*=5.9 Hz, 1H, NH), 4.55 (ABq, *J*=11.8 Hz, 2H, Hh and Hh'), 4.59 (ABq, *J*=11.8 Hz, 2H, Hg and Hg'), 5.01 (ddd, J_{He-Hf} =1.48 Hz, J_{He-Hf} '=3.7 Hz, and J_{Hd-He} =9.6 Hz, 1H, He), 5.06 (t, $J_{Ha-Hb'}$ =5.2 Hz, 1H, Ha), 6.33 (s, 1H, Ar-H), 6.37 (s, 1H, Ar-H), 7.23-7.39 (m, 10H, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 138.6, 138.3, 133.7, 133.1, 128.8, 128.3, 127.8, 127.6,

127.5, 127.4, 127.2, 120.9, 119.8, 78.5, 76.8, 73.4, 71.4, 69.7, 66.1, 49.0, 30.6, 18.6; FABMS: m/z 444 (M^+) 430, 203, 189, 173, 160, 154, 147, 136, 123, 109, 91, 79, 69; HRMS calcd for $C_{28}H_{32}N_2O_3$: 444.2412 found: 444.2403.

1-(2,3-Dihydro-1*H***-benzo[b][1,4]diazepin-3-yl)-1,3-diethoxy-(1***S***,2***R***)-propan-2-ol (3d).** Brow n crystalline solid, m.p.73-74 °C; IR (KBr): 3356, 2924, 2856, 1597, 1504, 1375, 1304, 1103, 745 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 1.20-1.35 (m, 6H), 2.05 (dt, *J*=5.0, 14.3 and 9.1 Hz, 1H), 2.38 (dd, *J*=3.6 and 14.3 Hz, 1H), 3.30-3.78 (m, 8H), 3.80 (m, 1H), 4.15 (brs, 1H, NH), 4.98 (ddd, *J*=2.1, 4.0 and 9.8 Hz, 1H), 5.07 (d, *J*=5.0 Hz, 1H), 6.58-6.80 (m, 4H, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 136.4, 135.6, 121.3, 120.5, 119.5, 118.4, 78.5, 69.9, 66.7, 65.9, 49.4, 30.5, 29.6, 15.6, 15.0; FABMS: m/z 292 (M⁺.) 176, 146, 120, 91, 71, 57; HRMS calcd for C₁₆H₂₄N₂O₃: 292.1786 found: 292.1775.

1,3-Diethoxy-1-(7-methyl-2,3-dihydro-1*H***-benzo[b][1,4]-diazepin-3-yl)-(1***S***,2***R***)-propan-2-ol** (**3e).** Brown crystalline solid, m.p.68-69 °C; IR (KBr): 3356, 2924, 2856, 1597, 1504, 1375, 1304, 1103, 745 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 1.20-1.27 (m, 6H), 2.05 (dt, *J*=5.0, 14.3 and 9.1 Hz, 1H), 2.17 (s, 3H), 2.35 (dd, *J*=3.6 and 9.8 Hz, 1H), 3.35-3.75 (m, 8H), 3.85 (m, 1H), 4.10 (brs, 1H, NH), 4.95 (ddd, *J*=2.1, 4.0 and 9.8 Hz, 1H), 5.07 (d, *J*=4.5 Hz, 1H), 6.36-6.54 (m, 3H, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 135.5, 133.8, 130.0, 121.7, 119.5, 119.2, 78.5, 76.5, 69.9, 66.7, 65.9, 64.8, 49.2, 30.5, 20.4, 15.6, 15.0; FABMS: m/z 306 (M⁺.) 217, 203, 185, 175, 165, 159, 133, 121, 107, 95, 69, 55; HRMS calcd for C₁₇H₂₆N₂O₃: 306.1943 found: 306.1932.

1-(7,8-Dimethyl-2,3-dihydro-1*H*-benzo[b][1,4]diazepin-3-yl)-1,3-diethoxy-(1*S*,2*R*)-propan-**2-ol (3f).** Brown crystalline solid, m.p. 56-58 °C; IR (KBr): 3354, 2972, 2922, 2865, 2361, 1615, 1517, 1448, 1304, 1117, 1023, 869, 770 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 1.24 (m, 6H), 2.06 (dt, *J*=5.2, 14.2 and 8.9 Hz, 1H), 2.09 (d, *J*=2.4 Hz, 6H), 3.42-3.75 (m, 8H), 3.84 (m, 1H), 4.08 (d, *J*=6.5 Hz, 1H), 4.12 (brs, 1H, NH), 4.95 (ddd, *J*=2.4, 4.2 and 6.5 Hz, 1H), 5.08 (d, *J*=4.9 Hz, 1H), 6.33 (s, 1H, Ar-H), 6.41 (s, 1H, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 133.9, 133.4, 128.6, 128.1, 121.0, 119.8, 78.7, 76.5, 70.1, 67.2, 65.3, 64.5, 49.5, 30.4, 29.1, 18.5, 15.3, 14.6; FABMS: m/z 320 (M⁺.) 173, 147, 119, 109, 95, 81, 69, 55; HRMS calcd for C₁₈H₂₈N₂O₃: 320.2099 found: 320.2087.

1-(2,3-Dihydro-1*H***-benzo[b][1,4]diazepin-3-yl)-2-hydroxy-3-methyl carboxyloxy-(1***S***,2***R***) - propyl acetate (3g).** Pale yellow crystalline solid, m.p. 89-90 °C; IR (KBr): 3376, 2924, 1736, 1598, 1508, 1370, 1305, 1243, 1106, 1044, 748 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 2.10 (s, 3H), 2.1-2.2 (m, 1H), 2.13 (s, 3H), 2.39 (dd, *J*=3.2 and 14.7 Hz, 1H), 3.5 (brs, 1H, NH), 3.9 (bd, *J*=3.2 Hz, 1H), 4.10-4.20 (m, 2H), 4.37 (dd, *J*=4.1 and 12.3 Hz, 1H), 4.82 (dd, *J*=3.2 and 9.8 Hz, 1H), 5.15 (t, *J*=4.9 Hz, 1H), 5.31 (ddd, *J*=2.4, 4.9 and 6.5 Hz, 1H), 6.56-6.8 (m, 4H, Ar-H); ¹³C NMR (75 MHz, CDCl₃): δ 170.9, 170.1, 135.9, 135.3, 121.9, 121.3, 119.5, 118.8, 78.7, 70.8, 63.5, 63.2, 49.7, 29.9, 21.0, 20.8; FABMS: m/z 320 (M⁺.) 219, 191, 154, 136, 91, 69, 57; HRMS calcd for C₁₆H₂₀N₂O₅: 320.1372 found: 320.1356.

Entry	Diamine	Aldehyde	Product ^a	Reaction time (min)	Yield(%) ^b
1a	NH ₂ NH ₂	OCH OBn OCH OBn	BnO. H N OF	─OBn H 15 min	85
1b	Me NH ₂ NH ₂	и	BnO H N N	∕—OBn 12 min DH	80
1c	Me NH ₂ Me NH ₂	u	BnO H Me N	∕──OBn 10 min OH	78
1d	NH ₂ NH ₂	OCH OEt	H N N	← OEt 0H 10 min	85
1e	Me NH ₂ NH ₂	'n	Me N	∕—OEt 12 min DH	79
1f	Me NH ₂ Me NH ₂	n	H Me Me N	← OEt OH 15 min	75
1g	NH ₂ NH ₂	11	AcQ H N OH	DAc 10 min	86

Table 1. Synthesis of 1,5-diazepines from *o*-phenyldiamines and α , β -unsaturated aldehyde

^a Products were characterized by 1H NMR, 13C NMR, IR and mass spectroscopy. ^b Yield refers to pure products after chromatography.

References and Notes

1. Schutz, H. Benzodiazepines Springer: Heidelberg, 1982. (b) Landquist, J. K. In Comprehensive Heterocyclic Chemistry: Katritzky, A. R.; Rees, C. W.; Pergamon: Oxford, 1984; Vol. 1. pp 166-170. Schutz, H. *Benzodiazepines*: Springer: Heidelberg, 1982. (b) Landquist, J. K. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, C. W.; Pergamon: Oxford, 1984; Vol. 1. pp 166-170.

- 2. Randall, L. O.; Kappel, B. *Benzodiazepines*: Garattini, S.; Mussini, E.; Randall, L. O. Eds., Raven Press: New York, 1973; p 27.
- 3. (a) Haris, R. C.; Straley, J. M.; U. S. Patent 1 537 757, 1968; Chem. Abstr. 1970, 73, 100054w.
- 4. De Baun, J. R.; Pallos, F. M.; Baker, D. R. U. S. Patent 3 978 227, 1976; *Chem. Abstr.* **1977**, 86, 5498d.
- (a) Essaber, M.; Baouid, A.; Hasnaoui, A.; Benharref, A.; Lavergne, J. P. Synth. Commun. 1998, 28, 4097. (b) El-Sayed, A. M.; Abdel-Ghany, H.; El-Saghier, A. M. M. Synth. Commun. 1999, 29, 3561. (c) Reddy, K. V. V.; Rao, P. S.; Ashok, D. Synth. Commun. 2000, 30, 1825.
- 6. Stahlhofen, P.; Ried, W. Chem. Ber. 1957, 90, 815. (b) Reid, W.; Torinus, E. Chem. Ber. 1959, 92, 2902.
- Balakrishna, M. S.; Kaboudin, B. *Tetrahedron Lett.* 2001, 42, 1127. (b) Curini, M.; Epifano,
 F.; Marcotullio, M. C.; Rosati, O. *Tetrahedron Lett.* 2001, 42, 3193. (c) Zhong, W.; Zhang,
 Y.; Chen, X. *Tetrahedron Lett.* 2001, 42, 73.
- 8. Li, C. J.; Chan, T. H. *Tetrahedron* **1999**, *55*, 11149. (b) Babu, G.; Perumal, P. T.; *Aldrichima Acta* **2000**, *33*, 16. (c) Ghosh, R. *Indian. J. Chem.* **2001**, *40B*, 550.
- 9. Acyclic α,β-unsaturated aldehyde was prepared from D-glucal using a procedure reported in literature: Wengel, J.; Lau, J.; Pedersen, E. B. *Synthesis* **1989**, 829.